Abstract:The genetic basis of antipsychotic drug efficacy is likely polygenic in nature. Genetic risks of schizophrenia may also be related to antipsychotic drug response. The Psychiatric Genomics Consortium (PGC) Genome-Wide Association Study (GWAS) provided evidence of association with schizophrenia risk for many Single Nucleotide Polymorphism (SNP) across the genome. We examined whether Polygenic Risk Scores (PRS) based on the PGC GWAS are predictive of antipsychotic efficacy in four cohorts of patients with first episode psychosis (total n=510): 1) Zucker Hillside Hospital First Episode schizophrenia trial (ZHH-FE), 2) European First Episode Schizophrenia Trial (EUFEST), 3) Spanish First Episode Psychosis study (SFEP), and 4) the clinical trial as part of the Center for Intervention Development and Applied Research at ZHH (CIDAR). The discovery cohort was the ZHH-FE with 77 patients (mixed ethnicity) randomized to risperidone or olanzapine. Three replication cohorts were: 1) EUFEST with 141 patients (all Caucasian) randomized to five antipsychotics; 2) SFEP with 192 patients (all Caucasian) on various antipsychotics; and 3) CIDAR with 100 patients (mixed ethnicity) randomized to risperidone or aripiprazole. Genotyping was performed using the Illumina Omni-1Quad (EUFEST and ZHH-FE) or Illumina Infinium HumanOmniExpressExome platform (CIDAR and SFEP). SNP imputation was conducted with IMPUTE2 against the full 1000 Genomes v3 reference panel. PRS was computed based on the results of the PGC GWAS using PRSice software for the discovery cohort with thresholds at PT<5E-8, 0.001, 0.01, 0.05, 0.10, 0.20, 0.50. Based on the findings from the discovery cohort, PRS was computed for the three replication cohorts using a threshold of PT<0.01. Symptom measure was the total score of Brief Psychiatric Rating Scale (BPRS) for ZHH-FE, SFEP, and CIDAR, or Positive and Negative Symptoms Scale (PANSS) for EUFEST. Hierarchical linear regression was performed on the 3-month symptom score with the PRS as the predictor while controlling for age, sex, and baseline symptom score. Genomic principal component scores were also covaried to control for population stratification for ZHH-FE and CIDAR. In the ZHH-FE cohort, higher PRS at the thresholds of PT<0.01, 0.05, 0.10, 0.20, and 0.50 significantly predicted higher symptom scores at 3-month follow-up, explaining 6–8% of the variance (all p's<0.05). PT<0.01 gave the strongest result in the discovery sample, and was used to replicate the findings in the other three cohorts. Higher PRS significantly predicted worse symptoms in EUFEST and SFEP cohorts, explaining 3.5% and 3.7% of variance, (p's<0.01), but not in the CIDAR sample. Combining the four cohorts in a meta-analysis, PRS was significantly predictive of 3-month symptom scores (pooled partial r=0.18, p=0.002). Higher PRS was associated with higher symptom scores at 3-month follow-up, suggestive of less improvement in treatment. The overall results remained significant when only European ancestry individuals were included in the analysis. These findings suggest that polygenic risk scores for schizophrenia may also be related to antipsychotic drug response. Patients with higher polygenic risk scores tended to have less improvement with antipsychotic drug treatment. Further analysis is needed to elucidate a more refined genomic profile for antipsychotic drug response.

Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis

A Polygenic Risk Score Analysis of Psychosis Endophenotypes Across Brain Functional, Structural, and Cognitive Domains.

Psychosis Endophenotypes: A Gene-Set-Specific Polygenic Risk Score Analysis.

Effect of Polygenic Scores on the Relationship Between Psychosis and Cognitive Performance

Polygenic Burden Analysis of Longitudinal Clusters of Psychopathological Features in A Cross-Diagnostic Group of Individuals with Severe Mental Illness

Polygenic Scores and Networks of Psychopathology Symptoms

Genetic Analysis of Psychosis Biotypes: Shared Ancestry-Adjusted Polygenic Risk and Unique Genomic Associations

A Genome-wide Association Analysis of a Broad Psychosis Phenotype Identifies Three Loci for Further Investigation

Use of Schizophrenia and Bipolar Disorder Polygenic Risk Scores to Identify Psychotic Disorders

Attention-mediated genetic influences on psychotic symptomatology in adolescence

Multivariate Genetic Correlates of the Auditory Paired Stimuli-Based P2 Event-Related Potential in the Psychosis Dimension From the BSNIP Study.

Integrating Polygenic Allele Burden Information and Phenomic Data to Characterize Complex Disease Trajectories in Severe Mental Illness

Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study

Genetic risk for bipolar disorder and schizophrenia predicts structure and function of the ventromedial prefrontal cortex

Polygenic and Polyenvironment Interplay in Schizophrenia-Spectrum Disorder and Affective Psychosis; the EUGEI First Episode Study

Associations between psychosis endophenotypes across brain functional, structural, and cognitive domains.

The effect of polygenic risk score and childhood adversity on transdiagnostic symptom dimensions at first-episode psychosis: evidence for an affective pathway to psychosis

SCHIZOPHRENIA POLYGENIC RISK SCORE PREDICTS ANTIPSYCHOTIC TREATMENT RESPONSE IN PATIENTS WITH FIRST EPISODE PSYCHOSIS

Novel Gene-Brain Structure Relationships in Psychotic Disorder Revealed Using Parallel Independent Component Analyses.

Schizophrenia polygenic risk scores, clinical variables and genetic pathways as predictors of phenotypic traits of bipolar I disorder

Polygenic risk scores mediating functioning outcomes through cognitive and clinical features in youth at family risk and controls